Madrigal Mental Care

Madrigal Mental Care Overview

Madrigal Mental Care is focused on using nanotechnology to accurately deliver psychedelic drugs for the treatment of mental health conditions such as post-traumatic stress disorder (PTSD). The company's Nanovo intranasal spray is designed to deliver active, nanoencapsulated psychedelic substances directly to the brain for rapid, safe, and efficient uptake. Madrigal utilizes molecules composed of psychedelic drugs such as psilocybin, ketamine, mescaline, MDMA, and more. By fundamentally changing the coding in the brain, rather than simply treating symptoms, the company is able to offer a transformative solution with minimal side effects.

Latest News

Mar 13, 2024 · finance.yahoo.com

growth-positive

Madrigal Announces Groundbreaking Ketamine Research for PTSD Treatment and Upcoming In-Human Clinical Trials

Madrigal Mental Care has announced the successful completion of its nanotechnology research on the use of Ketamine for treating trauma-related disorders like PTSD and depression. The company is now preparing to initiate in-human clinical trials. The research highlights the potential of Ketamine combined with Madrigals proprietary nanotechnology to offer a transformative approach to PTSD treatment. The company aims to begin human trials this year and expedite FDA approval processes, aiming to provide a revolutionary treatment by 2026.

InvestmentExpand

May 9, 2022 · www.prnewswire.com

growth-positive

Madrigal Mental Care Develops Treatment for Post-Traumatic Stress Disorder Based on Psychedelic Drugs

Madrigal Mental Care, a biopharmaceutical company, introduces its novel nanotechnology for the treatment and prevention of post-traumatic stress disorder (PTSD) at Biomed Israel 2022. The company has developed a breakthrough nasal spray that enables nose-to-brain delivery of biodegradable nanoparticles encapsulating psychedelic substances. The technology was developed by Prof. Amnon Sintov of Ben-Gurion University of the Negev and licensed from BGN Technology. The nanotechnology platform allows for the precise and safe delivery of psychoactive substances, offering a new approach to psychedelic-based treatments. Madrigal Mental Care aims to begin preclinical trials with rodents and achieve efficacy and safety approvals to start first-in-human clinical trials next year. The companys technology has the potential to revolutionize the field of mental health care.

PartnersInvestment

May 9, 2022 · www.israel21c.org

growth-positive

Novel nasal spray delivers psychedelic drugs for PTSD

Israeli biopharmaceutical company Madrigal Mental Care is developing a novel nasal spray to deliver psychedelic drugs to the brain for treating and preventing post-traumatic stress disorder (PTSD). The company will introduce the nanotechnology-based delivery system at the Biomed Israel 2022 conference. The experimental spray contains biodegradable nanoparticles encapsulating molecules of psychedelic substances. The technology was licensed to Madrigal Mental Care by BGN Technologies. The company aims to begin first-in-human clinical trials next year.

CustomersPartners

Funding

Team Members

4

Employees: 1-10

Web & Social Links

Locations

Re'im, Israel

Photos & Videos

No files yet

Madrigal Mental Care Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info